r
c
l
e
n
f
b
r
c
articl
histori
flo
chrysanthemi
flower
chrysanthemum
morifolium
ramat
wide
use
china
metabolit
luteolin
vivo
cathecholomethyltransferas
comt
howev
lack
pharmacokinet
inform
chrysoeriol
diosmetin
oral
administr
flo
keyword
chrysanthemi
extract
fce
present
studi
aim
develop
hplcuv
method
luteolin
simultan
determin
rat
plasma
concentr
luteolin
apigenin
chrysoeriol
chrysoeriol
diosmetin
util
pharmacokinet
studi
four
compound
oral
give
fce
diosmetin
rat
method
success
valid
appli
pharmacokinet
studi
oral
pharmacokinet
administr
fce
rat
without
cogiv
comt
inhibitor
entacapon
chrysoeriol
flo
chrysanthemi
diosmetin
detect
rat
plasma
oral
administr
fce
catecholomethyltransferas
comt
concentr
significantli
decreas
cogiv
entacapon
furthermor
auc
luteolin
significantli
increas
entacapon
chrysoeriol
decreas
entacapon
reveal
comt
might
play
import
role
disposit
luteolin
rat
dose
fce
conclus
sensit
accur
reproduc
hplcuv
method
simultan
determin
luteolin
apigenin
chrysoeriol
diosmetin
rat
plasma
develop
pharmacokinet
chrysoeriol
diosmetin
combin
luteolin
apigenin
character
oral
administr
fce
rat
gave
us
inform
pharmacokinet
potenti
pharmacolog
effect
fce
vivo
flower
chrysanthemum
morifolium
ramat
flo
chrysanthemi
tradit
chines
medicin
wide
use
healthi
food
thousand
year
mani
studi
report
healthi
benefit
antioxid
cardiovascular
protect
hepatoprotect
effect
antiarrhythm
effect
anticomplementari
activ
sever
acut
respiratori
syndrom
new
drug
candid
flo
chrysanthemi
extract
fce
treatment
cardiovascular
diseas
clinic
trial
china
luteolin
apigenin
fig
two
main
bioactiv
ingredi
fce
two
typic
flavonoid
also
wide
distribut
fruit
veget
exhibit
anticanc
cancer
prevent
antiinflammatori
neuroprotect
agent
past
studi
luteolin
apigenin
mainli
underw
conjug
metabol
uridin
diphosphoglucuronosyltransferas
ugt
sulfotransferas
sult
vivo
recent
luteolin
identifi
good
substrat
catecholomethyltransferas
comt
two
methyl
metabolit
luteolin
chrysoeriol
diosmetin
identifi
rat
plasma
hydrolylsi
treatment
intraven
given
luteolin
rat
sinc
flavonoid
occur
mainli
glucuronid
sulfat
form
blood
circul
lack
standard
compound
glucuronid
sulfat
flavonoid
total
form
free
glucuronid
sulfat
flavonoid
analyz
hydrolysi
treatment
previou
studi
chrysoeriol
diosmetin
possess
mani
biolog
effect
similar
luteolin
antioxid
antiinflammatori
also
exhibit
effect
osteoporosi
furthermor
chrysoeriol
diosmetin
natur
prodrug
cancer
prevent
could
convert
luteolin
cyp
therefor
crucial
studi
pharmacokinet
chrysoeriol
diosmetin
fce
oral
taken
hand
luteolin
exhibit
much
faster
elimin
rate
apigenin
fce
oral
administr
rat
comt
probabl
import
mechan
caus
luteolin
lower
exposur
howev
need
confirm
role
comt
disposit
luteolin
oral
dose
fce
rat
therefor
present
studi
aim
develop
improv
quantit
method
determin
luteolin
apigenin
chrysoeriol
diosmetin
rat
plasma
use
hplcuv
util
pharmacokinet
studi
four
flavonoid
rat
oral
administr
fce
without
comt
inhibitor
entacapon
pharmacokinet
data
could
give
us
inform
pharmacokinet
potenti
pharmacolog
effect
fce
vivo
materi
method
luteolin
apigenin
purchas
hangzhou
skyherb
technolog
co
ltd
hangzhou
china
puriti
diosmetin
obtain
shaanxi
huangteng
biotechnolog
co
ltd
sian
china
puriti
chrysoeriol
synthes
depart
medicin
chemistri
colleg
pharmaceut
scienc
zhejiang
univers
puriti
fce
provid
institut
materi
medica
zhejiang
univers
china
contain
ww
luteolin
ww
apigenin
determin
hplc
hydrolysi
hydrochlor
acid
entacapon
purchas
jinan
wedo
industri
co
ltd
jinan
china
puriti
methanol
acetonitril
formic
acid
water
hplcgrade
chemic
standard
commerci
sourc
highest
qualiti
avail
analysi
perform
use
highperform
liquid
chromatograph
system
agil
technolog
usa
equip
onlin
degass
autosampl
vwd
detector
thermost
column
compart
male
spragu
dawley
rat
weigh
g
obtain
experiment
anim
center
zhejiang
academi
medic
scienc
procedur
accord
approv
anim
use
protocol
zhejiang
univers
hous
cage
expos
h
lightdark
cycl
free
access
food
water
anim
fast
free
access
water
h
experi
h
drug
administr
hplc
analysi
perform
agil
zorbax
sbc
column
mm
mobil
phase
consist
formic
acid
acetonitril
methanol
constant
rate
mlmin
inject
volum
wavelength
set
nm
quantit
analysi
proport
compon
mobil
phase
optim
obtain
well
separ
luteolin
apigenin
chrysoeriol
diosmetin
intern
standard
quercetin
stock
standard
solut
luteolin
apigenin
chrysoeriol
diosmetin
approxim
mgml
intern
standard
quercetin
approxim
mgml
prepar
dissolv
appropri
amount
refer
methanol
respect
seri
work
solut
contain
luteolin
apigenin
chrysoeriol
diosmetin
prepar
subsequ
dilut
stock
solut
methanol
reach
concentr
rang
work
solut
quercetin
also
prepar
rat
plasma
sampl
prepar
accord
method
develop
laboratori
modif
brief
detect
total
form
free
glucuronid
sulfat
flavonoid
plasma
hydrolyz
hydrochlor
acid
h
ml
tube
ml
ethyl
acet
contain
quercetin
ad
mixtur
vortex
min
tube
centrifug
min
rpm
ml
supernat
organ
phase
care
transfer
anoth
ml
tube
evapor
dryness
vacuum
desicc
room
temperatur
residu
reconstitut
mobil
phase
concentr
luteolin
apigenin
chrysoeriol
diosmetin
determin
hplc
method
describ
method
valid
accord
guidanc
preclin
pharmacokinet
studi
chemic
drug
recommend
state
food
drug
administr
sfda
china
blank
plasma
least
six
rat
blank
plasma
spike
four
analyt
sampl
obtain
rat
oral
administr
fce
process
assay
describ
interfer
endogen
exogen
materi
occur
retent
time
luteolin
apigenin
chrysoeriol
diosmetin
quercetin
calibr
curv
rang
assess
weight
least
squar
liner
regress
base
analytequercetin
peak
area
ratio
prepar
triplic
lloq
defin
lowest
concentr
could
quantit
precis
accuraci
b
standard
sampl
spike
luteolin
apigenin
chrysoeriol
diosmetin
low
medium
high
concentr
analyt
use
accuraci
precis
studi
five
replic
concentr
process
analyz
describ
accuraci
studi
assay
recoveri
extract
recoveri
calcul
intraand
interday
precis
rel
standard
deviat
rsd
evalu
analyz
homogen
sampl
five
replic
consecut
day
intraand
interday
precis
rsd
requir
freezethaw
shortterm
h
longterm
day
stock
solut
h
day
postprepar
stabil
autosampl
h
luteolin
apignin
chrysoeriol
diosmetin
evalu
accord
fda
guidanc
http
low
medium
high
concentr
analyt
triplic
use
stabil
studi
except
stock
solut
stabil
mgml
analyt
use
data
express
remain
initi
determin
male
spraguedawley
rat
randomli
alloc
fce
entacapon
fce
group
five
rat
rat
fast
h
free
access
water
dose
mgkg
fce
combin
without
mgkg
entacapon
dissolv
wv
oral
administ
entacapon
fce
fce
group
respect
blood
sampl
collect
orbit
venou
sinu
heparin
tube
predos
postdos
h
centrifug
g
min
plasma
collect
store
analysi
pharmacokinet
paramet
calcul
pharmacokinet
softwar
da
china
differ
fce
entacapon
fce
group
compar
ttest
two
tail
use
excel
microsoft
chrysoeriol
diosmetin
possess
ident
logp
valu
due
similar
structur
fig
could
separ
well
use
mixtur
formic
acid
methanol
formic
acid
acetonitril
use
formic
acid
acetonitril
methanol
could
significantli
improv
separ
optim
combin
mobil
phase
formic
acid
acetonitril
methanol
vvv
obtain
success
separ
analyt
luteolin
apigenin
chrysoeriol
diosmetin
intern
standard
quercetin
fig
quercetin
select
intern
standard
due
similar
structur
four
analyt
would
exhibit
behavior
similar
analyt
sampl
extract
chromatograph
elut
specif
method
plasma
matrix
evalu
plasma
six
rat
typic
chromatogram
blank
plasma
sampl
b
blank
plasma
sampl
spike
luteolin
apigenin
chrysoeriol
diosmetin
quercetin
c
plasma
sampl
rat
min
oral
administr
mgkg
fce
shown
fig
interfer
endogen
substanc
rat
plasma
observ
retent
time
interest
sampl
treat
hydrolysi
prepar
peak
area
ratio
luteolin
apigenin
chrysoeriol
diosmetin
quercetin
display
good
linear
relationship
rang
typic
regress
equat
follow
r
n
luteolin
r
n
apigenin
r
n
chrysoeriol
r
n
diosmetin
lloq
analyt
recoveri
precis
accuraci
data
present
tabl
extract
recoveri
luteolin
apigenin
chrysoeriol
diosmetin
respect
assay
recoveri
luteolin
apigenin
chrysoeriol
diosmetin
respect
intraday
precis
rsd
luteolin
apigenin
chrysoeriol
diosmetin
b
respect
interday
precis
rsd
b
respect
mean
extract
recoveri
quercetin
sampl
detail
data
shown
freezethaw
shortterm
longterm
stabil
result
luteolin
apigenin
chrysoeriol
diosmetin
rat
plasma
shown
tabl
reveal
four
analyt
rel
stabl
addit
four
analyt
stock
solut
h
day
stabl
remain
initi
determin
four
analyt
intern
standard
quercetin
analyz
process
hplc
autosampl
h
stabl
remain
initi
determin
method
success
appli
analysi
plasma
obtain
rat
follow
singl
oral
dose
mgkg
fce
without
mgkg
entacapon
concentrationtim
profil
luteolin
apigenin
chrysoeriol
diosmetin
give
fce
without
mgkg
entacapon
shown
fig
plasma
concentr
luteolin
entacapon
fce
group
significantli
higher
fce
group
auc
c
max
luteolin
significantli
increas
entacapon
coadminist
fce
tabl
wherea
plasma
concentr
chrysoeriol
diosmetin
auc
chrysoeriol
significantli
decreas
chrysoeriol
diosmetin
quercetin
c
plasma
sampl
min
oral
administr
mgkg
fce
rat
sampl
treat
hydrolysi
previou
pharmacokinet
studi
fce
rat
dog
human
mainli
focus
luteolin
apigenin
glucuronid
sulfat
form
methyl
metabolit
luteolin
chrysoeriol
diosmetin
never
mention
sinc
chrysoeriol
diosmetin
similar
structur
close
logp
valu
share
mass
spectrum
optim
chromatograph
condit
import
present
studi
studi
agil
zorbax
sbc
column
mm
appli
separ
flavonoid
get
suitabl
mobil
phase
condit
mixtur
formic
acid
acetonitril
formic
acid
methanol
three
compar
combin
three
compon
mobil
phase
found
make
well
separ
optim
proport
acetonitril
methanol
mobil
phase
formic
acid
acetonitril
methanol
vvv
determin
addit
chrysoeriol
diosmetin
still
free
hydroxyl
could
conjug
ugt
sult
therefor
hydrolysi
treatment
sampl
import
assay
methyl
metabolit
luteolin
vivo
method
success
util
plasma
pharmacokinet
luteolin
apigenin
chrysoeriol
diosmetin
oral
administr
mgkg
fce
coadministr
without
mgkg
entacapon
rat
plasma
concentrationtim
profil
chrysoeriol
diosmetin
obtain
indic
two
flavonoid
would
exhibit
biolog
effect
vivo
fce
taken
methyl
luteolin
permeabl
vivo
due
rel
higher
hydrophob
luteolin
might
easili
distribut
tissu
addit
two
methyl
luteolin
could
demethyl
cyp
also
could
play
biolog
effect
luteolin
vivo
hand
compar
control
group
concentr
luteolin
entacapon
fce
group
significantli
increas
methyl
metabolit
obvious
decreas
indic
comt
might
play
role
disposit
luteolin
vivo
luteolin
could
methyl
comt
apigenin
specul
comt
might
mechan
respons
fig
meanplasma
concentrationtim
profil
luteolin
apigenin
chrysoeriol
diosmetin
oral
administr
mgkg
fce
without
cogiv
mgkg
entacapon
rat
data
express
mean
sem
n
compar
entacapon
cme
group
p
b
p
b
pharmacokinet
differ
luteolin
apigenin
oral
fce
rat
present
studi
directli
evalu
role
comt
vivo
disposit
luteolin
oral
dose
fce
rat
howev
increas
concentr
luteolin
comt
inhibit
limit
could
revers
pharmacokinet
differ
luteolin
apigenin
possibl
inhibit
comt
entacapon
limit
due
wide
tissu
distribut
comt
vivo
andor
metabol
enzym
ugt
sult
especi
small
intestin
could
compet
comt
decreas
contribut
comt
disposit
luteolin
concentr
apigenin
also
increas
entacapon
mechan
unclear
need
investig
conclus
present
studi
provid
method
simultan
determin
luteolin
apigenin
chrysoeriol
diosmetin
rat
plasma
success
util
pharmacokinet
studi
fce
rat
also
could
appli
futur
clinic
studi
fce
pharmacokinet
two
methyl
luteolin
vivo
could
enlarg
knowledg
disposit
profil
luteolin
pharmacolog
effect
fce
vivo
oral
administr
fce
